牡蛎肽通过NF-κB/iNOS信号通路改善肝纤维化

doi:10.5246/jcps.2023.06.037

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (6): 435-445.DOI: 10.5246/jcps.2023.06.037

牡蛎肽通过NF-κB/iNOS信号通路改善肝纤维化

邓凯翔¹, 彭经宙², 张美泉³, 林慧娟¹, 王小华¹, 何道兴¹, 朱俊明¹, 陈明光¹, 黄津⁴^,^*()

1. 福建医科大学附属南平第一医院, 福建南平 353006
2. 杭州市萧山区第一人民医院感染性疾病科, 浙江杭州 311200
3. 福建省老年医院呼吸与危重症医学科, 福建福州 350003
4. 福建中医药大学附属第二人民医院感染科, 福建福州 350003

收稿日期:2022-12-07 修回日期:2023-01-21 接受日期:2023-02-16 出版日期:2023-07-01 发布日期:2023-07-01
通讯作者: 黄津
作者简介:
+ Tel.: +86-13859369873, E-mail: 531104142@qq.com
基金资助:
The Project of Youth Foundation of Fujian Province Health Department (Grant No. 2020QNB053).

Oyster peptide ameliorates hepatic fibrosis through the NF-κB/iNOS signaling pathway

Kaixiang Deng¹, Jingzhou Peng², Meiquan Zhang³, Huijuan Lin¹, Xiaohua Wang¹, Daoxing He¹, Junming Zhu¹, Mingguang Chen¹, Jin Huang⁴^,^*()

1 The First Hospital of Nanping affiliated with Fujian Medical University, The First Hospital of Nanping Affiliated to Fujian Medical University, Nanping 353006, China
2 Department of Infectious Diseases, The First People’s Hospital of Xiaoshan District, Hangzhou 311200, China
3 Department of Pulmonary and Critical Care Medicine, Fujian Provincial Geriatric Hospital, Fuzhou 350003, China
4 Department of Infectious Diseases, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350003, China

Received:2022-12-07 Revised:2023-01-21 Accepted:2023-02-16 Online:2023-07-01 Published:2023-07-01
Contact: Jin Huang

摘要/Abstract

摘要：

本文研究探讨牡蛎肽(OP)改善肝纤维化的机制可能是通过NF-κB/iNOS信号通路。将50只雄性SD大鼠采用随机数字表法随机分为5组: 对照组、模型组、低剂量(0.5 g/kg) OP组、中剂量(1.0 g/kg) OP组、高剂量(2.0 g/kg) OP组, 每组10只。皮下注射50%四氯化碳(CCl₄)建立肝纤维化大鼠模型6周。结果发现, OP治疗组中, CCl₄诱导的肝纤维化大鼠肝脏中I型胶原、III型胶原和TGF-β1表达水平均显著低于模型组(P < 0.05)。OP可以下调大鼠的肝组织NF-κB和iNOS的表达, 可能是通过介导NF-κB/iNOS信号通路改善大鼠肝纤维化。

关键词: 肝纤维化, 牡蛎肽, 核因子-κB, 诱导型一氧化氮合酶

Abstract:

In the present study, we found that oyster peptide (OP) could ameliorate hepatic fibrosis through the NF-κB/iNOS signaling pathway. A total of 50 male Sprague-Dawley rats were randomly divided into five groups by the random digital table method: control group, model group, low-dose (0.5 g/kg) OP group, medium-dose (1.0 g/kg) OP group, and high-dose (2.0 g/kg) OP group, with 10 rats in each group. The rat model of hepatic fibrosis was established by subcutaneous injection of 50% carbon tetrachloride (CCl₄). In OP therapy groups, the expressions of collagen I, collagen III, and TGF-β1 in the liver with CCl₄-induced hepatic fibrosis were significantly lower than those in the model group (P < 0.05). OP could down-regulate the expressions of NF-κB and iNOS in the liver tissue of rats with hepatic fibrosis. Collectively, OP ameliorated hepatic fibrosis, possibly through the NF-κB/iNOS signaling pathway.

Key words: Hepatic fibrosis, Oyster peptide, NF-κB, Inducible nitric oxide synthase

Supporting:

邓凯翔, 彭经宙, 张美泉, 林慧娟, 王小华, 何道兴, 朱俊明, 陈明光, 黄津. 牡蛎肽通过NF-κB/iNOS信号通路改善肝纤维化[J]. 中国药学(英文版), 2023, 32(6): 435-445.

Kaixiang Deng, Jingzhou Peng, Meiquan Zhang, Huijuan Lin, Xiaohua Wang, Daoxing He, Junming Zhu, Mingguang Chen, Jin Huang. Oyster peptide ameliorates hepatic fibrosis through the NF-κB/iNOS signaling pathway[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 435-445.

图/表 6

Table 1. Primer sequences.

Figure 1. The liver morphology of rats in each group was observed. (A) Control group; (B) Model group; (C) Low-dose group; (D) Medium-dose group; (E) High-dose group.

Figure 2. The comparison of pathological liver staining in each group (×100). Masson staining results (A1–E1): collagen fiber, mucus and cartilage were blue. Muscle fiber, cellulose and red blood cells are red; the nuclei are bluish-black. TUNEL staining results (A2–E2). (A) Control group; (B) Model group; (C) Low-dose group; (D) Medium-dose group; (E) High-dose group.

Figure 3. The expression of collagen I, collagen III, and TGF-β1 protein in liver tissue sections of each group (10×10). (A) Control group; (B) Model group; (C) Low-dose group; (D) Medium-dose group; (E) High-dose group; (F) *P < 0.05, **P < 0.01 vs. model group. ▲P < 0.05, ▲▲P < 0.01 vs. control group.

Figure 4. The expressions of NF-κB and iNOS at the mRNA level in the liver tissue of each group. (A) Control group; (B) Model group; (C) Low-dose group; (D) Medium-dose group; (E) High-dose group.

Figure 5. The expressions of NF-κB and iNOS at the protein level in the liver tissue of each group.

参考文献 27

[1]	Chiabotto, G.; Ceccotti, E.; Tapparo, M.; Camussi, G.; Bruno, S. Human liver stem cell-derived extracellular vesicles target hepatic stellate cells and attenuate their pro-fibrotic phenotype. Front. Cell Dev. Biol. 2021, 9, 777462.
[2]	Liu, X.X.; Mi, X.J.; Wang, Z.; Zhang, M.; Hou, J.G.; Jiang, S.; Wang, Y.P.; Chen, C.; Li, W. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis. 2020, 11, 454.
[3]	Sato, K.; Kennedy, L.; Liangpunsakul, S.; Kusumanchi, P.; Yang, Z.H.; Meng, F.Y.; Glaser, S.; Francis, H.; Alpini, G. Intercellular communication between hepatic cells in liver diseases. Int. J. Mol. Sci. 2019, 20, 2180.
[4]	Zhou, G.; Lin, W.; Fang, P.; Lin, X.; Zhuge, L.; Hu, Z.; Jin, L. miR-10a improves hepatic fibrosis by regulating the TGFβl/Smads signal transduction pathway. Exp. Ther. Med. 2016, 12, 1719–1722.
[5]	Li, S.; Zhao, W.; Zhao, Z.; Cheng, B.; Li, S.; Liu, C. Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II‑induced hepatic stellate cells activation. Mol. Med. Rep. 2020, 22, 2191–2198.
[6]	Liu, F.; Zeng, J.X.; Zhu, D.L.; Xu, X.G.; Lan, M.L.; Wang, M.M.; Zhao, J.L.; Xia, H.M.; Zhang, Y.; Zhang, R.Z. PDGFA gene rs9690350 polymorphism increases biliary atresia risk in Chinese children. Biosci. Rep. 2020, 40, BSR20200068.
[7]	Zhang, T. Hu, J.; Wang, X.; Zhao, X.; Li, Z.; Niu, J.; Steer, C.J.; Zheng G.; Song, G. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway. J. Hepatol. 2019, 70, 87–96.
[8]	Luedde, T.; Schwabe, R.F. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 108–118.
[9]	Rodríguez, M.J.; Sabaj, M.; Tolosa, G.; Herrera Vielma, F.; Zúñiga, M.J.; González, D.R.; Zúñiga-Hernández, J. Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation. Cells. 2021, 10, 3406.
[10]	Kalayarasan, S.; Sriram, N.; Sudhandiran, G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sci. 2008, 82, 1142–1153.
[11]	Zheng, H.Y.; Wang, X.; Zhang, Y.; Chen, L.; Hua, L.; Xu, W. Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis. J. Ethnopharmacol. 2019, 244, 111856.
[12]	Sommerhalder, C.; Cummins, C.B.; Wang, X.; Ramdas, D.; Lopez, O.N.; Gu, Y.; Zhou, J.; Radhakrishnan, R.S. HJC0416 attenuates fibrogenesis in activated hepatic stellate cells via STAT3 and NF-κB pathways. J. Surg. Res. 2021, 261, 334–342.
[13]	Bai, F.; Huang, Q.; Nie, J.; Lu, S.; Lu, C.; Zhu, X.; Wang, Y.; Zhuo, L.; Lu, Z.; Lin, X. Trolline ameliorates liver fibrosis by inhibiting the NF-κB pathway, promoting HSC apoptosis and suppressing autophagy. Cell Physiol. Biochem. 2017, 44, 436–446.
[14]	Han, M.; Liu, X.; Liu, S.; Su, G.; Fan, X.; Chen, J.; Yuan, Q.; Xu, G. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces hepatic stellate cell (HSC) activation and liver fibrosis in C57BL6 mouse via activating Akt and NF-κB signaling pathways. Toxicol. Lett. 2017, 273, 10–19.
[15]	Yu, C.; Li, Y.; Chen, G.; Wu, C.; Wang, X.; Zhang, Y. Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges. J. Zhejiang Univ. Sci. B. 2022, 23, 547–563.
[16]	Xu, D.; Lin, F.; Zhu, X.Y.; Liu, W.Y.; Chen, X.W.; Feng, J.Q.; Fan, A.Q.; Cai, M.Y.; Xu, Y.J. Immunomodulatory effect of oyster peptide on immunosuppressed mice. J. Peking Univ. (Health Sci.). 2016, 48, 392–397.
[17]	Zhang, W. Wei, Y.; Cao, X.; Guo, K.; Wang, Q.; Xiao, X.; Zhai, X.; Wang, D.; Huang, Z. Enzymatic preparation of Crassostrea oyster peptides and their promoting effect on male hormone production. J. Ethnopharmacol. 2021, 264, 113382.
[18]	Osaki, K.; Shimizu, Y.; Yamamoto, T.; Miyake, F.; Kondo, S.; Yamaguchi, H. Improvement of liver function by the administration of oyster extract as a dietary supplement to habitual alcohol drinkers: a pilot study. Exp. Ther. Med. 2015, 10, 705–710.
[19]	Mao, Y.; Zhang, S.; Yu, F.; Li, H.; Guo, C.; Fan, X. Ghrelin attenuates liver fibrosis through regulation of TGF-β1 expression and autophagy. Int. J. Mol. Sci. 2015, 16, 21911–21930.
[20]	Kim, H.A.; Park, S.H.; Lee, S.S.; Choi, Y.J. Anti-wrinkle effects of enzymatic oyster hydrolysate and its fractions on human fibroblasts. J. Korean Soc. Food Sci. Nutr. 2015, 44, 1645–1652.
[21]	Wang, Y.K.; He, H.L.; Wang, G.F.; Wu, H.; Zhou, B.C.; Chen, X.L.; Zhang, Y.Z. Oyster (crassostrea gigas) hydrolysates produced on a plant scale have antitumor activity and immunostimulating effects in BALB/c mice. Mar. Drugs. 2010, 8, 255–268.
[22]	Gomez, H.L.R.; Peralta, J.P.; Tejano, L.A.; Chang, Y.W. In silico and in vitro assessment of Portuguese oyster (crassostrea angulata) proteins as precursor of bioactive peptides. Int. J. Mol. Sci. 2019, 20, E5191.
[23]	Zhou, M.Y.; Cheng, M.L.; Huang, T.; Hu, R.H.; Zou, G.L.; Li, H.; Zhang, B.F.; Zhu, J.J.; Liu, Y.M.; Liu, Y.; Zhao, X.K. Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and noncanonical pathways in hepatic stellate cells. World J. Gastroenterol. 2021, 27, 6908–6926.
[24]	Albadawy, R.; Agwa, S.H.A.; Khairy, E.; Saad, M.; El Touchy, N.; Othman, M.; El Kassas, M.; Matboli, M. Circulatory endothelin 1-regulating RNAs panel: promising biomarkers for non-invasive NAFLD/NASH diagnosis and stratification: clinical and molecular pilot study. Genes. 2021, 12, 1813.
[25]	An, Y.; Lin, S.Y.; Tan, X.J.; Zhu, S.O.; Nie, F.F.; Zhen, Y.H.; Gu, L.S.; Zhang, C.L.; Wang, B.C.; Wei, W.; Li, D.; Wu, J.H. Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif. 2021, 54, e12993.
[26]	Macías-Pérez, J.R.; Vázquez-López, B.J.; Muñoz-Ortega, M.H.; Aldaba-Muruato, L.R.; Martínez-Hernández, S.L.; Sánchez-Alemán, E.; Ventura-Juárez, J. Curcumin and α/β-adrenergic antagonists cotreatment reverse liver cirrhosis in hamsters: participation of nrf-2 and NF-κB. J. Immunol. Res. 2019, 2019, 3019794.
[27]	Gelzo, M.; Scialò, F.; Cacciapuoti, S.; Pinchera, B.; De Rosa, A.; Cernera, G.; Comegna, M.; Tripodi, L.; Schiano Moriello, N.; Mormile, M.; Fabbrocini, G.; Parrella, R.; Corso, G.; Gentile, I.; Castaldo, G. Inducible nitric oxide synthase (iNOS): why a different production in COVID-19 patients of the two waves? Viruses. 2022, 14, 534.

牡蛎肽通过NF-κB/iNOS信号通路改善肝纤维化

Oyster peptide ameliorates hepatic fibrosis through the NF-κB/iNOS signaling pathway

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 27

相关文章 5

编辑推荐

Metrics

本文评价

[1]	陈培杰, 张云天. PTP1B抑制肝纤维化逆转期TRAIL诱导的肝星状细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 867-880.
[2]	黄津, 邓凯翔, 黄美珍, 林高敏, 林媚, 练水梅, 张美泉. NF-κB抑制剂PDTC诱导人肝星状细胞LX-2凋亡的药理机制[J]. 中国药学(英文版), 2022, 31(9): 665-676.
[3]	张明康, 陈宇玥, 周燕, 武新安. 槲皮素对四氯化碳致大鼠肝纤维化的缓解作用及其机制研究[J]. 中国药学(英文版), 2022, 31(11): 840-852.
[4]	陈新, 修贺明, 姜慧卿^*. 苏拉明在肝纤维化大鼠肝星状细胞增殖和凋亡中的作用[J]. , 2011, 20(4): 415-420.
[5]	齐荔红, 康鲁平, 张俊平^*, 史宁, 张珉, 吴堂明. 染料木素和槲皮素体外抗肝纤维化作用[J]. , 2001, 10(4): 212-215.